Purchase Order 75F40126P00030

The Food and Drug Administration issued a delivery order to Pacific Biosciences of California, Inc. on July 24, 2023, with a ceiling value of $61,236.00 for specialized sequencing reagents and supplies including AmpurePB, barcoded overhang adapter kits, Sequel binding and internal control kits, Sequel pipet tips, sequencing kits, SMRT cell oil, SMRT cell trays, and SMRTbell express template preparation supplies. Place of performance is Silver Spring, MD 20993. The order was firm fixed price...

The Food and Drug Administration awarded a $47,897.16 delivery order to Pacific Biosciences of California, Inc. on March 30, 2026, for supplies and reagents supporting the PacBio Sequel IIe long-read DNA/RNA sequencer. This delivery order was issued under the FDA's existing Indefinite Delivery Indefinite Quantity (IDIQ) contract 75F40121D00007 with Pacific Biosciences, valued at $1 million and originally extending through March 2025. The work will be performed in Laurel, Maryland, with an...

<p>The Food and Drug Administration awarded a purchase order to University of Maryland, Baltimore on September 7, 2022, for RNA extraction, quality control assessment, library preparation, and Illumina sequencing of 200 peripheral blood samples collected in Paxgene tubes, with a ceiling value of $54,999.98 and completion date of September 29, 2023. Work is performed in Baltimore, Maryland. The order carries no set-aside designation and is priced on a firm fixed price basis.</p>

<p>The Food and Drug Administration awarded a purchase order to Pacific Biosciences of California, Inc. for $51,193.93 on August 23, 2023, for sequencing supplies. Place of performance is Menlo Park, California. The order was firm fixed price with no small business set-aside. Ultimate completion was scheduled for February 19, 2024. The procurement originated from a solicitation posted June 30, 2023 with a due date of July 10, 2023.</p>

<p>The Food and Drug Administration awarded a purchase order to Pacific Biosciences of California, Inc. valued at $28,815.00 on May 25, 2023 for sequencing kits 2.0 and SMRT cell 8M trays for Sequel II system, designated as a total small business set-aside. Work is performed at Menlo Park, California. The order is firm fixed price with completion due September 30, 2023. The solicitation was posted May 12, 2023 with a due date of May 22, 2023.</p>

<p>The Food and Drug Administration issued a delivery order to Illumina, Inc. on June 15, 2026, with a ceiling value of $313,463.14 for Illumina reagent chemistry kits.</p> <p>Place of performance is Berwyn Heights, MD. The order is firm fixed price and ultimate completion is July 19, 2026. No set-aside was used. The order covers specialized reagent kits supporting FDA genomic analysis and sequencing operations.</p>

This is a firm-fixed price purchase order awarded by the Food and Drug Administration (FDA) to Pacific Biosciences of California, Inc. for $24,357.60 to provide PacBio reagents. The contract has a completion date of September 30, 2024 and does not have a set-aside designation. Pacific Biosciences is the original equipment manufacturer of the Sequel and Sequel II DNA/RNA sequencing platforms, which are used by federal agencies like the FDA, CDC, USDA, and NIH to support genomic research across...

The U.S. Food and Drug Administration awarded a $48,715.20 firm fixed-price purchase order to Pacific Biosciences of California, Inc. for Revio reagent kits (part number 102-817-900) with an ultimate completion date of September 9, 2024. This award represents a direct procurement of consumable supplies critical to next-generation DNA sequencing operations. Pacific Biosciences is a leading biotechnology manufacturer headquartered in Menlo Park, California, specializing in advanced sequencing...

The Food and Drug Administration issued a purchase order to Creighton University for $154,452.00 on September 23, 2024. This is a no-cost modification extending the period of performance to March 13, 2026. Work is performed in Silver Spring, Maryland. The order funds further investigation of the association between β-lactamase enzyme expression and other proteins and antimicrobial resistance by studying additional gram-negative bacterial isolates. Pricing is firm fixed price with no small...

The Defense Health Agency awarded a $92,550 firm fixed-price call under its $5.3 million Blanket Purchase Agreement with Biodiscovery LLC (doing business as Daicel Arbor Biosciences) on May 24, 2024, with an ultimate completion date of June 18, 2024. The contract, which carries no set-aside designation, calls for the delivery of MYBAITS MITO 384 RXN reagent kits in a quantity of six units. MYBAITS reagents are proprietary custom DNA and RNA-based bait enrichment kits used for targeted genomic...